Edwards Lifesciences Corp
NYSE:EW 10:50:46 AM EDT
Other Pre-Announcement
Edwards Lifesciences Says Q4 Sales Grew 1% To $1.35 Billion; Constant Currency Sales Grew 7%
Published: 01/31/2023 21:45 GMT
Edwards Lifesciences Corp (EW) - Edwards Lifesciences - Q4 Sales Grew 1% to $1.35 Billion; Constant Currency Sales Grew 7%.
Edwards Lifesciences - Reiterated 2023 Guidance of 9 to 12 Percent Constant Currency Sales Growth.
Edwards Lifesciences - for Q1 of 2023, Co Projects Total Sales Between $1.37 and $1.45 Billion, & Adjusted EPS of $0.58 to $0.64.
Edwards Lifesciences - Expect Meaningful Growth and Progress in 2023 With a Gradual Improvement in Healthcare Staffing and Contributions From All Major Regions.
Edwards Lifesciences - Q4 EPS of $0.65; Q4 Adjusted EPS $0.64.
Q4 Earnings per Share View $0.61, Revenue View $1.33 Billion -- Refinitiv Ibes Data (analyst estimates).
Q1 Earnings per Share View $0.59, Revenue View $1.37 Billion -- Refinitiv Ibes Data (analyst estimates).
FY2023 Revenue View $5.77 Billion -- Refinitiv Ibes Data (analyst estimates).
Edwards Lifesciences - Reiterated 2023 Guidance of 9 to 12 Percent Constant Currency Sales Growth.
Edwards Lifesciences - for Q1 of 2023, Co Projects Total Sales Between $1.37 and $1.45 Billion, & Adjusted EPS of $0.58 to $0.64.
Edwards Lifesciences - Expect Meaningful Growth and Progress in 2023 With a Gradual Improvement in Healthcare Staffing and Contributions From All Major Regions.
Edwards Lifesciences - Q4 EPS of $0.65; Q4 Adjusted EPS $0.64.
Q4 Earnings per Share View $0.61, Revenue View $1.33 Billion -- Refinitiv Ibes Data (analyst estimates).
Q1 Earnings per Share View $0.59, Revenue View $1.37 Billion -- Refinitiv Ibes Data (analyst estimates).
FY2023 Revenue View $5.77 Billion -- Refinitiv Ibes Data (analyst estimates).